$1.74 Billion is the total value of Sofinnova Investments, Inc.'s 67 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 48.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Natera | $352,007,000 | +11.8% | 3,100,560 | 0.0% | 20.29% | +7.2% | |
| KRTX | Karuna Therapeutics, Inc. | $222,559,000 | -5.2% | 1,952,441 | 0.0% | 12.83% | -9.1% | |
| AVTE | New | Aerovate Therapeutics, Inc. | $85,811,000 | – | 3,758,686 | +100.0% | 4.95% | – |
| YMAB | Y-mAbs Therapeutics, Inc | $74,167,000 | +11.8% | 2,194,278 | 0.0% | 4.28% | +7.2% | |
| ASND | Ascendis Pharma A/Sadr | $68,659,000 | +2.1% | 521,923 | 0.0% | 3.96% | -2.2% | |
| AZN | Sell | AstraZeneca PLCadr | $57,482,000 | +11.6% | 959,632 | -7.3% | 3.31% | +7.0% |
| New | iShares TRput | $53,186,000 | – | 325,000 | +100.0% | 3.06% | – | |
| BOLT | Bolt Biotherapeutics, Inc. | $42,584,000 | -53.0% | 2,754,437 | 0.0% | 2.45% | -55.0% | |
| UTHR | Buy | United Therapeutics Corp | $38,768,000 | +7.8% | 216,085 | +0.5% | 2.23% | +3.3% |
| VERA | New | Vera Therapeutics, Inc.cl a | $38,650,000 | – | 2,914,776 | +100.0% | 2.23% | – |
| BIIB | New | Biogen Inc | $38,297,000 | – | 110,600 | +100.0% | 2.21% | – |
| INZY | Inozyme Pharma, Inc. | $34,562,000 | -13.9% | 2,028,308 | 0.0% | 1.99% | -17.5% | |
| GRTX | Galera Therapeutics, Inc | $30,313,000 | +11.5% | 3,083,712 | 0.0% | 1.75% | +6.9% | |
| XLRN | Buy | Acceleron Pharma Inc | $29,319,000 | +21.1% | 233,638 | +30.9% | 1.69% | +16.1% |
| ALGN | Buy | Align Technology Inc | $28,774,000 | +16.8% | 47,093 | +3.5% | 1.66% | +12.0% |
| PTCT | Buy | PTC Therapeutics Inc | $24,599,000 | +11.3% | 581,940 | +24.7% | 1.42% | +6.7% |
| INSM | Buy | Insmed Inc | $24,025,000 | +14.0% | 844,169 | +36.4% | 1.38% | +9.3% |
| SRPT | New | Sarepta Therapeutics, Inc. | $23,205,000 | – | 298,500 | +100.0% | 1.34% | – |
| New | ARK ETF TRput | $23,125,000 | – | 250,000 | +100.0% | 1.33% | – | |
| HRTX | New | Heron Therapeutics Inc | $22,778,000 | – | 1,467,675 | +100.0% | 1.31% | – |
| CMPI | Checkmate Pharmaceuticals Inc | $21,496,000 | -50.9% | 3,606,707 | 0.0% | 1.24% | -52.9% | |
| NXTC | Nextcure, Inc | $21,455,000 | -19.8% | 2,671,856 | 0.0% | 1.24% | -23.1% | |
| PTGX | Sell | Protagonist Therapeutics Inc | $20,155,000 | +18.8% | 449,082 | -31.4% | 1.16% | +13.9% |
| NBIX | New | Neurocrine Biosciences, Inc. | $19,775,000 | – | 203,200 | +100.0% | 1.14% | – |
| EXEL | Buy | Exelixis Inc | $19,672,000 | +3.8% | 1,079,681 | +28.7% | 1.13% | -0.5% |
| AKUS | Akouos, Inc | $19,014,000 | -9.5% | 1,515,074 | 0.0% | 1.10% | -13.2% | |
| PODD | Buy | Insulet Corp | $18,804,000 | +311.8% | 68,500 | +291.4% | 1.08% | +295.6% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $17,787,000 | +81.1% | 88,214 | +93.0% | 1.02% | +73.7% |
| RGNX | Buy | Regenxbio Inc | $16,618,000 | +34.7% | 427,740 | +18.2% | 0.96% | +29.1% |
| NCNA | Nucana Biomed Ltdadr | $15,512,000 | -44.5% | 5,599,999 | 0.0% | 0.89% | -46.8% | |
| AGEN | Sell | Agenus Inc | $15,207,000 | +60.7% | 2,769,900 | -20.4% | 0.88% | +54.0% |
| DXCM | Buy | Dexcom Inc | $14,395,000 | +48.3% | 33,713 | +24.9% | 0.83% | +42.4% |
| OBSV | ObsEva SA | $14,391,000 | -6.8% | 4,749,623 | 0.0% | 0.83% | -10.7% | |
| ITCI | Sell | Intra-Cellular Therapies Inc | $12,783,000 | -42.5% | 313,159 | -52.2% | 0.74% | -44.8% |
| MRTX | Sell | Mirati Therapeutics Inc | $12,686,000 | -46.3% | 78,538 | -43.1% | 0.73% | -48.6% |
| AGIO | New | Agios Pharmaceuticals, Inc. | $12,071,000 | – | 219,033 | +100.0% | 0.70% | – |
| RETA | Sell | Reata Pharmaceuticals Inc | $11,266,000 | -52.6% | 79,601 | -66.6% | 0.65% | -54.6% |
| QURE | Sell | Uniqure NV | $9,989,000 | -30.6% | 324,303 | -24.1% | 0.58% | -33.4% |
| AMGN | Buy | Amgen Inc | $9,872,000 | +2.1% | 40,500 | +4.2% | 0.57% | -2.1% |
| CYTK | Buy | Cytokinetics Inc | $9,525,000 | +5.1% | 481,323 | +23.5% | 0.55% | +0.7% |
| KURA | Buy | Kura Oncology Inc | $9,265,000 | +294.1% | 444,372 | +434.3% | 0.53% | +278.7% |
| Nucana Biomed Ltdordinary shares | $6,648,000 | -44.5% | 2,400,000 | 0.0% | 0.38% | -46.8% | ||
| MGNX | Buy | MacroGenics Inc | $6,299,000 | +170.2% | 234,504 | +220.4% | 0.36% | +159.3% |
| CCXI | Buy | ChemoCentryx Inc | $6,235,000 | -32.4% | 465,637 | +158.7% | 0.36% | -35.2% |
| Sell | Marinus Pharmaceuticals Inc | $6,210,000 | +8.3% | 346,160 | -6.5% | 0.36% | +3.8% | |
| CHRS | Coherus BioSciences | $6,010,000 | -5.3% | 434,555 | 0.0% | 0.35% | -9.4% | |
| CYT | New | Cyteir Therapeutics, Inc. | $5,671,000 | – | 265,000 | +100.0% | 0.33% | – |
| New | FibroGen, Inc.put | $5,326,000 | – | 200,000 | +100.0% | 0.31% | – | |
| IMTX | Buy | Immatics NV | $5,148,000 | +19.2% | 443,370 | +15.1% | 0.30% | +14.2% |
| AMRN | Amarin Corpadr | $5,127,000 | -29.5% | 1,170,584 | 0.0% | 0.30% | -32.5% | |
| TCRR | Sell | TCR2 Therapeutics Inc | $4,862,000 | -34.6% | 296,282 | -12.0% | 0.28% | -37.4% |
| CLDX | New | Celldex Therapeutics, Inc. | $4,505,000 | – | 134,724 | +100.0% | 0.26% | – |
| MIRM | Sell | Mirum Pharmaceuticals Inc | $4,486,000 | -52.5% | 259,465 | -45.5% | 0.26% | -54.4% |
| JNCE | Buy | Jounce Therapeutics Inc | $4,248,000 | -19.2% | 624,756 | +22.1% | 0.24% | -22.5% |
| FATE | Sell | Fate Therapeutics Inc | $4,026,000 | -10.9% | 46,386 | -15.3% | 0.23% | -14.7% |
| ALGS | Sell | Aligos Therapeutics Inc | $3,344,000 | -20.7% | 164,051 | -11.6% | 0.19% | -24.0% |
| New | ChemoCentryx Inccall | $2,879,000 | – | 215,000 | +100.0% | 0.17% | – | |
| OTIC | Otonomy Inc | $2,790,000 | -12.6% | 1,251,256 | 0.0% | 0.16% | -16.1% | |
| REPL | Sell | Replimune Group Inc | $2,753,000 | -36.6% | 71,661 | -49.6% | 0.16% | -39.1% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $2,508,000 | -34.9% | 158,609 | -58.1% | 0.14% | -37.5% |
| New | ACADIA Pharmaceuticals Inccall | $2,439,000 | – | 100,000 | +100.0% | 0.14% | – | |
| New | TCR2 Therapeutics Incput | $2,292,000 | – | 139,700 | +100.0% | 0.13% | – | |
| SYBX | Synlogic Inc. | $2,237,000 | +8.7% | 574,972 | 0.0% | 0.13% | +4.0% | |
| SVRA | Sell | Savara Inc | $2,173,000 | -39.9% | 1,278,424 | -26.4% | 0.12% | -42.4% |
| PDSB | PDS Biotechnology Corporation | $1,790,000 | +175.8% | 142,635 | 0.0% | 0.10% | +164.1% | |
| CTIC | New | CTI BioPharma Corp | $429,000 | – | 171,619 | +100.0% | 0.02% | – |
| SRRA | New | Sierra Oncology, Inc. | $49,000 | – | 2,500 | +100.0% | 0.00% | – |
| CALA | Exit | Calithera Biosciences Inc | $0 | – | -757,533 | -100.0% | -0.11% | – |
| PBYI | Exit | Puma Biotechnology Inc | $0 | – | -344,917 | -100.0% | -0.20% | – |
| Exit | Heron Therapeutics Inccall | $0 | – | -250,000 | -100.0% | -0.24% | – | |
| Exit | Aptose Biosciences Inc | $0 | – | -696,928 | -100.0% | -0.25% | – | |
| ARNA | Exit | Arena Pharmaceuticals Inc | $0 | – | -91,448 | -100.0% | -0.38% | – |
| SNDX | Exit | Syndax Pharmaceuticals Inc | $0 | – | -298,644 | -100.0% | -0.40% | – |
| Exit | ChemoCentryx Incput | $0 | – | -150,000 | -100.0% | -0.46% | – | |
| ATHA | Exit | Athira Pharma, Inc. | $0 | – | -509,168 | -100.0% | -0.56% | – |
| HZNP | Exit | Horizon Therapeutics PLC | $0 | – | -133,997 | -100.0% | -0.74% | – |
| Exit | Gilead Sciences Inccall | $0 | – | -300,000 | -100.0% | -1.17% | – | |
| MRUS | Exit | Merus N.V. | $0 | – | -1,311,039 | -100.0% | -1.65% | – |
| LLY | Exit | Eli Lilly and Co | $0 | – | -180,501 | -100.0% | -2.03% | – |
| JAZZ | Exit | Jazz Pharmaceuticals PLC | $0 | – | -255,928 | -100.0% | -2.53% | – |
| Exit | Health Care Select Sector SPDRput | $0 | – | -400,000 | -100.0% | -2.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.